https://scholars.lib.ntu.edu.tw/handle/123456789/628839
Title: | Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC | Authors: | Wu, Yi-Long Lu, Shun CHIH-HSIN YANG Zhou, Jianying Seto, Takashi Ahn, Myung-Ju Su, Wu-Chou Yamamoto, Noboru Kim, Dong-Wan Paolini, Jolanda Usari, Tiziana Iadeluca, Laura Wilner, Keith D Goto, Koichi |
Keywords: | Asia; Crizotinib; NSCLC; Phase 2; ROS1 | Issue Date: | Oct-2022 | Journal Volume: | 3 | Journal Issue: | 10 | Source: | JTO clinical and research reports | Abstract: | Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data were immature. Here, we present the final OS, quality of life (QoL), and safety data after an additional 3 years of follow-up. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628839 | ISSN: | 26663643 | DOI: | 10.1016/j.jtocrr.2022.100406 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.